# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Development Candidate targets Glypican-3 for the treatment of solid tumors, including hepatocellular carcinomaNomination trigge...
Piper Sandler analyst Edward Tenthoff reiterates Moderna (NASDAQ:MRNA) with a Overweight and maintains $214 price target.
Evercore ISI Group analyst Cory Kasimov maintains Moderna (NASDAQ:MRNA) with a In-Line and maintains $120 price target.
The CDC's ACIP recommends RSV vaccines for adults 75+, and for those 60-74 with chronic conditions. GSK's Arexvy is app...
- Reuters
- Reuters
The CDC's Advisory Committee on Immunization Practices is set to discuss recommendations for RSV, influenza, and COVID-19 v...